Medical Device News Magazine

Readygo Diagnostics Initiates An Assay Development Contract With Gemina Laboratories For The Detection Of Dengue From Saliva Samples

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • The Geo platform provides rapid results in any location in under 30 minutes and is expected to play a crucial role in the detection of DENV within near-patient settings which would greatly improve patient management and outcome.

ReadyGo Diagnostics Ltd. (ReadyGo), a specialist in isothermal molecular diagnostics, today announced that it has entered into a second assay development agreement with Gemina Laboratories Ltd. (Gemina) (CSE: GLAB) (FRA:8I7), a Canadian company that specialises in fast, affordable and accurate diagnostic tests.

ReadyGo Diagnostics will develop, optimize and validate an assay for the detection of the dengue virus (DENV) for Gemina to run on ReadyGo’s off-grid isothermal diagnostic platform, Geo. The Geo platform provides rapid results in any location in under 30 minutes and is expected to play a crucial role in the detection of DENV within near-patient settings which would greatly improve patient management and outcome.

Dengue fever is a viral infection caused by DENV. It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. Four serotypes of the virus have been found, all of which can cause the full spectrum of disease.  ReadyGo’s assay will detect all four serotypes.

Almost half of the world’s population, about 4 billion people, live in areas with a risk of dengue. DENV is a significant public health concern in many tropical and subtropical regions of the world, including parts of Southeast Asia, the Pacific Islands, the Caribbean, and Central and South America.  Each year, up to 400 million people are infected by a dengue virus. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue.

The symptoms of dengue fever can vary from mild to severe and typically appear 4 to 7 days after the mosquito bite. Common symptoms include high fever, severe headache (usually behind the eyes), joint and muscle pain, rash, and mild bleeding (such as nose or gum bleeding). In more severe cases, dengue can progress to a severe form known as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which can be life-threatening.

There is a huge need to test patients outside of the laboratory setting in the village or rural areas of low resource settings.  Often these communities cannot travel for central testing so rely on outreach services for sample collection which then presents significant issue of logistics to transport using cold chain to centralised laboratories.

ReadyGo’s isothermal PCR test will diagnose patients within 30 minutes in decentralised settings.  This would allow deployment outside of the laboratory and early diagnosis allows for timely medical intervention and appropriate management to prevent complications associated with severe dengue.

Severe dengue is a medical emergency. It requires immediate medical care at a clinic or hospital.

Early detection and prompt medical care can help prevent complications and reduce the risk of severe dengue.

Brian Firth, CEO of Gemina, commented: “I’m delighted about our partnership with ReadyGo Diagnostics, which extends beyond our TB test to include the creation of a second test on the Geo platform. At Gemina Labs, our mission is to develop enhanced diagnostic tests for infectious diseases. Our primary focus lies in creating efficient tests that can be utilized at the forefront of patient care, whether that involves field settings, home environments, or primary clinics. This is why ReadyGo’s platform, Geo, has left a strong impression on us – particularly in its potential applications for diagnosing and managing dengue fever. I hold a strong belief that through our partnership with ReadyGo, we’ll have the capability to produce a rapid and precise solution for detecting DENV, ultimately leading to tangible improvements in patient outcomes.”

Ben Cobb, CEO of ReadyGo Diagnostics, added: “We are delighted to further our collaboration with Gemina to develop a sensitive and quick DENV diagnostic assay. There is a pressing need for a decentralised test, particularly in resource-constrained areas. ReadyGo has some really innovative technology and we are fully dedicated to becoming the preferred development partner for companies striving to design straightforward and economical molecular diagnostic solutions across various contexts.”

Financial terms of the agreement have not been disclosed.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.